

Trial Name	Disease	Target	Key Inclusion Criteria*	Key Exclusion Criteria*	Publications	PI	Contact
An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMA-7) NCT04855136	Multiple Myeloma	BCMA	≥ 3 lines of therapy	Non-secretory MM History of or active plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome or amyloidosis.	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT05020015	B-cell Non-Hodgkin Lymphoma	CD19	≥2 lines of therapy DLBCL FL MZL	CNS involmen Burkitt's lymphoma MCL lymphoplasmocytic Richter's lymphoma	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769
A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies NCT04649112	B-cell Non-Hodgkin Lymphoma	CD 19	≥2 lines of therapy DLBCL FL MZL MCL CLL/SLL Burkitt's lymphoma Richter's lymphoma	CNS involmen	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769

Trial Name	Disease	Target	Key Inclusion Criteria*	Key Exclusion Criteria*	Publications	PI	Contact
A Phase 1/2 Feasibility, Safety, And Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects with Previously Treated Advanced Solid Tumors NCT02744287	Prostate Cancer	PSCA	Metastatic castration-resistant adenocarcinoma of the prostate (CRPC)	Impending fracture	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769
A Phase 1 Study of RTX-321 for the Treatment of Patients with Advanced Malignancies Associated with Human Papillomavirus-16 Infection NCT04672980	Cervical Anal Head & Neck	HPV 16 E7-specific CD8+ T cells	1) Disease progression following platinum-based or mitomycin C-based chemotherapy 2) All patients with PD-L1+ cervical cancer and those with HNSCC must have received or have been determined to be ineligible for immunotherapy with a PD-1 or PD-L1 inhibitor. 3) Confirmation of HLA-A*02:01 positive status by central testing	Progressive CNS disease	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769

Trial Name	Disease	Target	Key Inclusion Criteria*	Key Exclusion Criteria*	Publications	PI	Contact
Phase 1/2 Study of RTX-240 as a Monotherapy and in Combination with Pembrolizumab NCT04372706	NSCLCA		RR NSCLCA	Progressive CNS disease	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769
Adaptimmune: A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors NCT04044859	Gastric, H&N RCC Urothelial Ovarian NSCLCA	MAGE-A4	HLA-A*02 MAGE-A4 positive tumors	Progressive CNS disease	Article	Dr. Matthew Carabasi	Kledia Kaliqi 215.955.8546 Natisha Muhammad 215.955.5769
A Phase 1 multicenter study evaluating the safety and efficacy of ALLO-316 following ALLO-647 containing conditioning regimen in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) NCT04696731	Clear Cell Renal Cell Carcinoma	CD70	Must have received an immune checkpoint inhibitor and a VEGF-targeted therapy in the advanced or metastatic setting.	Progressive CNS disease	Article	Dr. Usama Gergis	Natisha Muhammad 215.955.5769